

Age-specific onset and distribution of the natural anticoagulant deficiency in pediatric thromboembolism

Masako Ichiyama¹, Shouichi Ohga², Masayuki Ochiai¹, Koichi Tanaka¹, Yuka Matsunaga¹, Takeshi Kusuda¹, Hirosuke Inoue¹, Masataka Ishimura³, Tomohito Takimoto³, Yui Koga⁴, Taeko Hotta⁴, Dongchon Kang⁴ and Toshiro Hara^{1,3}

BACKGROUND: The early diagnosis of inherited thrombophilia in children is challenging because of the rarity and hemostatic maturation.

METHODS: We explored protein C (PC), protein S (PS), and antithrombin (AT) deficiencies in 306 thromboembolic patients aged ≤ 20 y using the screening of plasma activity and genetic analysis.

RESULTS: Reduced activities were determined in 122 patients (40%). Low PC patients were most frequently found in the lowest age group (0–2 y, 45%), while low PS or low AT patients were found in the highest age group (16–20 y; PS: 30% and AT: 20%). Genetic study was completed in 62 patients having no other causes of thromboembolism. Mutations were determined in 18 patients (8 PC, 8 PS, and 2 AT genes). Six of eight patients with PC gene mutation were found in age 0–2 y (75%), while six of eight patients with PS gene mutation were in 7–20 y. Two AT gene-mutated patients were older than 4 y. Four PC-deficient and two PS-deficient patients carried compound heterozygous mutations. All but one PC gene-mutated patient suffered from intracranial thromboembolism, while PS/AT gene-mutated patients mostly developed extracranial venous thromboembolism.

[Q1] **CONCLUSION:** Stroke in low PC infants and deep vein thrombosis in low PS/AT school age children could be targeted for genetic screening of pediatric thrombophilias.

Thromboembolism is a multifactorial disease involving genetic predispositions, underlying disorders, and varied triggers including infection or injury. Vascular, circulatory, and hemostatic conditions are distinctively associated with the development of arterial and venous thromboses. Thromboembolism, formerly recognized as a rare event in children (1), has been increasingly diagnosed as a complication of sepsis, cancer, cardiovascular disease, and therapy-related events. Recent advances in the intensive cares, cardiac surgery, and transplantation medicine along with the imaging diagnosis may contribute to the increased number of pediatric patients with thrombosis (2,3). The established genetic risks of venous thromboembolism (VTE) include protein C (PC),

protein S (PS), and antithrombin (AT) deficiency, as well as factor V G1691A (FVL) and prothrombin G20210A (FII) variants (4). The high incidence of VTE in Caucasians (5) is explained by the fact that FVL and FII G20210A carriers were found in 20–60% of adult VTE patients in Caucasian but not Asian ancestries (6–9). PC, PS, and AT deficiencies share the lower prevalence than FVL and/or FII G20210A carriers, but the higher risk of the first and recurrent VTE than the other thrombophilias. On the other hand, the diagnosis is challenging during infancy and early childhood, because the references of increasing anticoagulant activity range widely until adolescence (10,11). The true effect of the natural anticoagulant deficiencies on the development of pediatric thromboembolism remains elusive because of the rare occurrence and the elaborative genetic screenings.

To clarify the clinical impact of the inherited deficiency of natural anticoagulant on children, we conducted the genetic analysis of PC, PS, and AT deficiency after the screening of each activity for pediatric patients with thromboembolism over 20 y in a single institution. The results demonstrated the distinct presentation of PC and PS deficiencies in infants and children, respectively, reflecting the genotype of adult Japanese patients.

RESULTS

Distribution of Thromboembolic Patients

Of 306 patients aged ≤ 20 y (male: female 1:1.14), 186 suffered from intracranial lesions including ischemic and/or hemorrhagic strokes. The extracranial lesions consisted of renal vein thrombosis ($n = 7$), purpura fulminans ($n = 3$), deep vein thrombosis in the leg ($n = 15$), and pulmonary thromboembolism ($n = 9$). Patients younger than 3 y were 27% of all patients. The largest age group was < 1 y of age ($n = 50$, 16.3%), and the number of other age groups were similar (median: 12, ranging: 9–17 (3.0–5.5%)).


PC, PS, and AT Activities in Patients

A total of 122 patients had the reduced activity of either anticoagulant; 95 with low PC (31%), 48 with low PS (16%), and 20 patients with low AT activity (7%; **Figure 1**). Low PC patients

[Q2] ¹Comprehensive Maternity and Perinatal Care Center, Kyushu University Hospital, Fukuoka, Japan; ²Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan; ³Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ⁴Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka, Japan. Correspondence: Shouichi Ohga (ohgas@yamaguchi-u.ac.jp)

Received 5 March 2015; accepted 29 June 2015; advance online publication 00 Month 2015. doi:10.1038/pr.2015.180

were most frequently determined in the lowest age group (0–2 y, 45%), while low PS or low AT patients were frequently found in the highest age group (16–20 y; PS: 30% and AT: 20%). The number of patients with low activity in age groups are shown in **Figure 2**. The proportions of low PC patients were higher than those of low PS or AT patients in age 0–2 (each <0.00001) and 13–15 y (0.0001, 0.0155), respectively. The proportion of low PC or PS patients (19%) was each higher than that of low AT patients in 7–12 y (0.0005). The number of patients showing both low levels of PC and PS activities were 25 (20%), 5 of whom had the low levels of all three factors (**Supplementary Figure S1** online).



[Q3] **Figure 1.** Flowchart of the genetic study of pediatric thrombophilia in a Japanese institution. During the 20 y, 306 patients (≤ 20 y of age) were screened by the plasma activities of protein C (PC), protein S (PS), and anti-thrombin (AT) and underwent the genetic study if they have idiopathic or unusual thrombophilic predispositions.




Figure 2. Proportion of patients who showed the low plasma activity of PC, PS, and AT according to the age groups. 0–2 y: infants ($n = 84$; low PC, 45%; low PS, 8%; low AT, 5%), 3–6 y: preschoolers ($n = 53$; low PC, 14%; low PS, 8%; low AT, 4%), 7–12 y: elementary school children ($n = 73$; low PC, 19%; low PS, 19%; low AT, 1%), 13–15 y: junior high school students ($n = 41$; low PC, 44%; low PS, 17%; low AT, 5%), 16–20 y: high school and college or university students ($n = 55$; low PC, 33%; low PS, 30%; low AT, 20%). Closed bar represents the patients who showed each low plasma activity. * $P = 0.0155$; ** $P = 0.0005$; † $P = 0.0001$; †† $P < 0.00001$. ns, no statistical significance.

Mutations of PC, PS, and AT Genes in Patients

Of 62 children who showed the low level of at least one factor, mutation carriers were found in low PC ($n = 8/39$, 21%), PS ($n = 8/27$, 30%), or AT ($n = 2/5$, 40%) patients, respectively. Forty-four patients carried no mutations. Age distribution of 62 patients differed among three deficiencies (0.0042; **Figure 3**). The proportion of age 0–2 y patients with PC deficiency (44%) was the highest among any age group patients with PS or AT deficiency. Six of eight patients with PC gene mutations (75%) were found in the age group 0–2 y, in which only two PS and no AT mutation carriers were determined. Four of eight patients with PS gene mutations (50%) were found in the age group 7–12 y. No ratio of mutated to analyzed patients differed in the age-groups.

Clinical Onset, Genotype, and Activity Levels of PC, PS, and AT in the Mutation Carriers

Eighteen patients with a mutation are listed in **Table 1**. Seven out of eight PC-deficient patients suffered from intracranial thromboembolism and five of them were younger than 2 y. On the other hand, six of eight PS-deficient patients presented in the second decade of life, the onset of which were adult type deep vein thrombosis of pulmonary thromboembolism in five of them. Double allele (homozygous or compound heterozygous) and one allele (heterozygous) mutation(s) were found in half of eight PC-deficient patients, respectively. On the other hand, double allele mutated patients were only two of eight heritable PS-deficient patients, both of whom carried PS-Tokushima. Two other patients had PS-Tokushima. Both patients with heritable AT deficiency carried heterozygote AT mutation. Four of eight patients with PC gene mutation and




Figure 3. Age distribution of patients with thromboembolism carrying PC, PS, and AT gene mutation. The circle size represents the number of patients. (a) PC deficiency ($n = 39$): 0–2 y, 44%; 3–6 y, 13%; 7–12 y, 8%; 13–15 y, 23%; and 16–20 y, 13%. Six of eight patients with PC gene mutations (75%) were found in the age group 0–2 y. (b) PS deficiency ($n = 27$): 0–2 y, 15%; 3–6 y, 15%; 7–12 y, 33%; 13–15 y, 4%; and 16–20 y, 33%. Four of eight (50%) patients were found in the age group 7–12 y. (c) AT deficiency ($n = 5$): 0–2 y, 20%; 3–6 y, 40%; 16–20 y, 40%. All AT gene mutation carriers were found in the age group more than 3 y. Closed areas indicate 0–2 y of age, open areas indicate 3–6 y of age, hatched areas indicate 7–12 y of age, gray areas indicate 13–15 y of age, and dotted areas indicate 16–20 y of age. * $P = 0.0042$, ** $P = 0.0019$. ns, no statistical significance.

[Q4]

Table 1. Plasma activity of protein C, protein S, and antithrombin and each gene mutation in pediatric patients

Patient	Sex	Age	Diagnosis	Plasma activity (%)			Mutation	Family history	Plasma activity (%) mother/father		
				PC	PS	AT			PC	PS	AT
PC deficiency											
<i>PROC</i>											
	F	6 d	Cerebral-VTE, twin-1	<5	45	111	Ex8; c.887C>T, p.Leu265Phe Ex9; c.1360G>C, p.Trp422Cys	Negative	63/63	69/99	125/110
	F	6 d	Cerebral-VTE, twin-2	<5	24	141	Ex8; c.887C>T, p.Leu265Phe Ex9; c.1360G>C, p.Trp422Cys	Negative	63/63	69/99	125/110
	F	9 d	ICH, PF	<10	140	60	Ex9; c.1109G>A, p.Val339Met Ex9; c.1362delG, p.Gly423ValfxX82 ^a	Negative	32/72	68/110	115/120
	F	13 d	Cerebral VTE	<5	29	110	Ex4; c.258delT, p.Leu55ArgfsX6 Ex9; c.905C>T, p.Arg271Trp	Negative	46/48	na/na	na/na
	M	4 mo	Intrahepatic bleeding	25	91	104	Ex7; c.671_673delAAG, p.Lys193del	Negative	64/93	67/95	97/101
	F	1 y	Meningitis, ICH/CI, PF	31	38	68	Ex4; c.356G>T, p.Asp88Tyr	Positive	50/99	66/83	na/105
	F	14 y	ICH, sinus thrombosis	32	62	87	Ex6; c.603A>G, p.Asp170Gly	na	na	na	na
	F	18 y	Cl lt. frontal	39	101	79	Ex3; c.293G>A, p.Glu67Lys	na	na	na	na
PS deficiency											
<i>PROS1</i>											
	M	3.5 mo	Thalamic bleeding, lt.	48	69	85	Ex6; c.927A>G, p.Lys196Glu ^c	na	na	na	na
	F	2 y	Hypoplasia of optic papilla lt.	90	61	116	Ex6; c.927A>G, p.Lys196Glu ^c	na	na	na	na
	F	10 y	DVT, epilepsy	60	10	na	Ex2; c.418-1G>C, Int1 splice acceptor site	na	na/92	<10/84	na
	M	11 y	DVT	5 ^b	12	122	Ex15; c.2361-2delAA, p.Lys674GlufsX24	na	na	na	na
	M	12 y	DVT	10 ^b	2	115	Ex1; c.391T>C, p.Leu17Pro Ex6; c.927A>G, p.Lys196Glu ^c	Positive	102/na	54/na	114/na
	F	12 y	IE, multiple CI	66	12	103	Ex13; c.1884C>T, p.Arg515Cys	Positive	na	69/low	na
	F	16 y	DVT	24	5	90	Ex13; c.1884C>T, p.Arg515Cys Ex6; c.927A>G, p.Lys196Glu ^c	na	103/107	14/71	97/97
	M	16 y	Thrombophlebitis, PTE	21	11	105	Ex12; c.1692C>T, p.Arg451X	na	119/101	29/129	109/116
AT deficiency											
<i>SERPINC1</i>											
	F	4 y	Vasculitis	121	74	14	Ex3; c.561T>C, p.Ser148Pro	Positive	104/na	30 ^d /na	58/na
	F	18 y	Pulmonary infarction	76	47	55	Ex7; c.1438T>C, p.Phe440Ser	na	113/na	67/na	65/na

The italic formatting indicates low activity according to the conditional limits of age groups.

CI, cerebral infarction; DVT, deep vein thrombosis; ICH, intracranial hemorrhage; lt., ; na, not assessed; PF, purpura fulminans; PTE, pulmonary thromboembolism; VTE, venous thromboembolism.

^aPC-Nagoya. ^bNo mutation of *PROC*. ^cPS-Tokushima. ^dAt 19 gestational weeks.

seven of eight patients with PS gene mutation showed reduced activities of PS and PC, respectively.

DISCUSSION

The first survey on PC, PS, and AT deficiency in Japanese thromboembolic children revealed the contribution to 5.9% of

pediatric thrombosis, and the age-dependent presentation of each PC, PS, or AT deficiency before adult life. Congenital PC and PS deficiencies were the major thrombophilias in Japanese children with different age distribution. Predominant cerebral thromboembolism in PC-deficiency contrasted sharply with extracranial VTE in the other two deficiencies. The

genotype of PS-deficient children reflected the high prevalence of PS-Tokushima in Japanese general population (1.1–1.8%; **Table 1**) (12,13). The Israeli-German cohort studies (14–16) have recently reported the prevalence of congenital deficiencies PC (7.4%), PS (8.2%), and AT (6.6%) in pediatric patients with thromboembolism aged 0.1–18 y. In the cohorts, the proportion of neonates was also higher in PC deficiency (32%; 8/25 patients) than seen in PS deficiency (10%; 3/30 patients) or AT deficiency (14%; 3/21 patients). Half of PC-deficient newborns presented cerebral sinovenous thrombosis and stroke. In this setting, PC-deficient infants characterized the phenotype of pediatric thrombophilias (purpura fulminans and intracranial lesions) beyond the ethnicity (17). The age-specific prevalence and phenotype of pediatric PC deficiency may be useful in the genetic screening for pediatric thrombophilias.

The first concern is the applicability of the lower limits of PC, PS, or AT activity in age groups for the genetic screening. The ranges of anticoagulant activities often vary until the attainment of adult levels, reflecting the individual maturation and vitamin K status (18,19). Our previous adult study assessed by the same measures reported that half of VTE patients with each low activity carried the heterozygous mutation, which resulted in 33% positive rate of all patients (20). Miyata *et al.* (21) confirmed that 32% of adult VTE patients carried heterozygous mutation of PC, PS, or AT, in the twice sample size, without the screening of plasma activity. In this setting, the concordant mutation rate by the independent studies would warrant the utility of plasma activities for genetic screening in Japanese children. No mutation in >30% of patients raises the possibility of large gene deletions, polymorphisms, and the other genetic variations or certain modifiers affecting the activity and antigen concentration (22). The present measures studied polymorphisms including the promoter regions but not deletions. Large deletions are reported to be 3–6% in these deficiencies (5). Cooper *et al.* (23) revealed that large deletions make up between 7 and 10% of PS and AT mutations and only 1% of PC mutations. The rare occurrence of thrombosis and the wide range of factor activities impeded to define the standard values of “true healthy” children who develop no thromboembolism until the forties. In this study, there was no significant difference in the ratios of mutated patients to the low PC patients who underwent the genetic analysis and in the ratios of mutated patients to the low PS patients analyzed in any age groups. Taking into account high safety margins, the limits of factor activity might be practical for the genetic screening of pediatric thrombophilias.

The proportion, genotype, and first presentation of PC, PS, and AT deficiency during childhood were distinct from those of adult patients. Patients with low PC activity were almost twice the number of those showing low PS activity (**Figure 1**). On the other hand, the number of patients who carried either *PROC* or *PROS1* mutation was the same eight. The first nationwide survey for pediatric thrombophilia in Japan suggested a higher prevalence of PC deficiency than expected (24,25). The discrepancy may be explained by the wider range of PC activity than that of PS or AT activity in infant and children

(18,26), partly arising from the inherent variation of PC pathway (27,28). Clinical manifestation and thrombin generation differ among the family members having the same *PROC* mutation (29). Otherwise, absolute PC deficiency rather than PS deficiency may contribute to the development of thromboembolism in the newborn and young infants (30). Half of the PS gene-mutated patients carried PS-Tokushima, two of whom had compound heterozygous mutations with one allele PS-Tokushima (**Table 1**). Both patients lacked PS activity and developed deep vein thrombosis at 12 and 16 y of age. These findings suggested that high allele frequency of PS-Tokushima made an impact on the genotype of severe PS-deficient children in Japan. By contrast, six of eight patients with PC deficiency presented in infancy, four of whom carried double allele mutation (one PC-Nagoya) having undetectable plasma activity. The genotypes of pediatric PC and PS deficiency corroborated the previous studies on Japanese adult population.

The other concern is the distinct affected site between PC-deficient (intracranial lesion) and PS-deficient children (extracranial VTE). Premature infants with perinatal complications are liable to bleed in the brain. However, intracranial lesions including sinovenous thrombosis were also observed in adolescence (**Table 1**). The expression levels of endothelial PC receptor and thrombomodulin are constitutively low in the brain compared with other organs. In contrast to the basilar arteries or choroid plexus, intracerebral vascular endothelium does not express thrombomodulin (31). Free PS works as a cofactor of activated PC in the PC pathway. Circulating free PS molecules are relatively high in infancy because of physiologically low C4-binding protein levels (26). It may explain the preferential cerebral lesions in PC-deficient children. Activated PC and thrombomodulin have homeostatic signals critical in regulating coagulation, inflammation, endothelial barrier function, and neuroprotection (32). PC-deficient children might be vulnerable to the brain damage in association with prothrombotic triggers.

One of the limitations in this report was that the results were obtained from a single center study. The number of mutation carriers was small even in the prolonged study. The other limitation was that the consumption effects and/or the plasma replacement therapy might not be completely excluded in assessing the activity levels of the natural anticoagulants. The shorter biological half-life of PC than that of PS or AT might influence the dissociated low activity of PC in infants. However, these findings do not explain the distinct presentation between PC deficiency in infancy and PS deficiency in adolescents or young adults. Multiplex ligation-dependent probe amplification and/or single-nucleotide polymorphism array are needed to search the deletion in the future study. Further comparative study on PC- and PS-deficient infants may shed some light on the pathophysiology and optimal management of pediatric thrombophilias.

In conclusion, PC gene-mutated patients mostly presented with intracranial thromboembolism than 2 y of age. On the other hand, PS/AT gene-mutated patients were preferentially found in school age children with extracranial VTE.

[Q6]

[Q7]

[Q8] The genetic screening of pediatric thrombophilias could be effectively targeted to stroke in low PC infants and deep vein thrombosis in low PS /AT school age children.

METHODS

Patients and Screening Protocol

From 1993 to 2012, 1,867 patients with thrombosis in Kyushu University and affiliated institutions were consecutively assessed for thrombophilic predispositions (Figure 1). After the exclusion of patients with anomaly and inborn errors of metabolism, 306 patients aged less than 21 y of age (16.4%) were enrolled for the study. Clinical information of thromboembolic events and/or coagulopathy was collected from the medical records and the interviews of attending doctors. Of 122 patients showing the low plasma activity, 60 were excluded because of acquired thrombotic disorders including vasculopathy, antiphospholipid syndrome, and autoimmune diseases. Finally, 62 patients underwent the genetic analysis because they had no explainable causes of thromboembolism other than PC, PS, or AT deficiency. Informed consent was obtained from parents of children aged <21 y of age. This study was certified by the Institutional Review Board of Kyushu University (#232-02, #448-00).

Coagulation Study

To exclude the consumption effects at the diagnosis of thromboembolism, the antigen/activity levels of PC, PS, and AT were repeatedly assessed when the clinical conditions were stabilized a couple of weeks to months after the onset of thromboembolism. The measurement of anticoagulation factors were performed as described previously (20,33). Anticoagulant activities of PC and PS were determined using the Staclot PC kit and the Staclot PS kit (Diagnostica Stago, Asnieres, France), respectively. A chromogenic substrate was used to assay for AT activity as heparin-dependent inhibition of bovine thrombin (Chromostate ATIII kit; Hitachi, Tokyo, Japan). The adult references were first standardized by using pooled normal plasma, in which a level below 3 SD was defined as reduced activity. According to the data in Japanese children (18,26), the lower limits of each activity were defined as follows: in age <90 d: PC 60%, PS 60%, and AT 65% of the adult reference levels (PC 75%, PS 60%, and AT 80%); 90 d–2 y: PC 85%, PS 85%, AT 65% of the adult levels; 3–6 y: each 85% of adults; and 7–20 y: same as the adults (Supplementary Table S1 online).

Gene Analysis of PC, PS, and AT

Genomic DNA was extracted from peripheral blood leukocytes. Direct sequencing of PC (*PROC* exon 1–9), PS (*PROS1* exon 1–15), and AT (*SERPINC1* exon 1–6) genes was performed as previously described (20). The exon and exon–intron boundary regions of each gene including promoter region were amplified by PCR, and the products were then subjected to direct sequencing using ABI 377 (Perkin Elmer Applied Biosystems, Foster City, CA).

Statistical Analysis

The median of continuous variables was assessed by the Mann–Whitney *U*-test. The distribution difference of countable variables was analyzed by chi-square test or Fisher's exact test. *P* values less than 0.05 were considered significant.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at <http://www.nature.com/pr>

ACKNOWLEDGMENTS

We thank Michiyo Urata, Takeshi Uchiumi (Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka, Japan), and Naotaka Hamasaki (Department of Clinical Chemistry, Faculty of Pharmaceutical Sciences, Nagasaki International University, Nagasaki, Japan) for the establishment of system, and all the staffs of the Department of Pediatrics, Kyushu University Hospital, Fukuoka, Japan for the clinical managements.

STATEMENT OF FINANCIAL SUPPORT

This study was supported by a grant from the Kyushu University Clinical Research Network Project and by a grant from the Ministry of Health, Labour and Welfare of Japan.

Disclosure: The authors have no conflict of interests to disclose.

REFERENCES

- Spentzouris G, Scriven RJ, Lee TK, Labropoulos N. Pediatric venous thromboembolism in relation to adults. *J Vasc Surg* 2012;55:1785–93.
- Nowak-Göttl U, Janssen V, Manner D, Kenet G. Venous thromboembolism in neonates and children—update 2013. *Thromb Res* 2013;131:Suppl 1:S39–41.
- Tolbert J, Carpenter SL. Common acquired causes of thrombosis in children. *Curr Probl Pediatr Adolesc Health Care* 2013;43:169–77.
- Caspers M, Pavlova A, Driesen J, et al. Deficiencies of antithrombin, protein C and protein S - practical experience in genetic analysis of a large patient cohort. *Thromb Haemost* 2012;108:247–57.
- Roberts LN, Patel RK, Arya R. Venous thromboembolism and ethnicity. *Br J Haematol* 2009;146:369–83.
- Shatla HM, Tomoum HY, Elsayed SM, et al. Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study. *Pediatr Neurol* 2012;47:114–8.
- Sirachainan N, Sasanakul W, Visudibhan A, Chuansumrit A, Wongwerawattanakoon P, Parapakpenjune S. Protein C deficiency in Thai children with thromboembolism: a report of clinical presentations and mutation analysis. *Thromb Res* 2010;125:200–2.
- Shen MC, Lin JS, Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. *Thromb Res* 2000;99:447–52.
- Tang L, Jian XR, Hamasaki N, et al. Molecular basis of protein S deficiency in China. *Am J Hematol* 2013;88:899–905.
- Holzhauser S, Goldenberg NA, Junker R, et al. Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembolism: an observational study. *Blood* 2012;120:1510–5.
- Sosothikul D, Kittikalayawong Y, Aungbamnet P, Buphachart C, Seksarn P. Reference values for thrombotic markers in children. *Blood Coagul Fibrinolysis* 2012;23:208–11.
- Sakata T, Okamoto A, Mannami T, Tomoike H, Miyata T. Prevalence of protein S deficiency in the Japanese general population: the Suita Study. *J Thromb Haemost* 2004;2:1012–3.
- Ikejiri M, Wada H, Sakamoto Y, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. *Int J Hematol* 2010;92:302–5.
- Limperger V, Klostermeier UC, Kenet G, et al. Clinical and laboratory characteristics of children with venous thromboembolism and protein C-deficiency: an observational Israeli-German cohort study. *Br J Haematol* 2014;167:385–93.
- Klostermeier UC, Limperger V, Kenet G, et al. Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study. *Thromb Haemost* 2015;113:426–33.
- Limperger V, Franke A, Kenet G, et al. Clinical and laboratory characteristics of paediatric and adolescent index cases with venous thromboembolism and antithrombin deficiency. An observational multicentre cohort study. *Thromb Haemost* 2014;112:478–85.
- Price VE, Ledingham DL, Krümpel A, Chan AK. Diagnosis and management of neonatal purpura fulminans. *Semin Fetal Neonatal Med* 2011;16:318–22.
- Ignjatovic V, Mertyn E, Monagle P. The coagulation system in children: developmental and pathophysiological considerations. *Semin Thromb Hemost* 2011;37:723–9.
- Berezcky Z, Kovács KB, Muszbek L. Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. *Clin Chem Lab Med* 2010;48:Suppl 1:S53–66.
- Kinoshita S, Iida H, Inoue S, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. *Clin Biochem* 2005;38:908–15.

21. Miyata T, Sato Y, Ishikawa J, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. *Thromb Res* 2009;124:14–8.
22. Oudot-Mellakh T, Cohen W, Germain M, et al. Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project. *Br J Haematol* 2012;157:230–9.
23. Cooper PC, Goodeve AC, Beauchamp NJ. Quality in molecular biology testing for inherited thrombophilia disorders. *Semin Thromb Hemost* 2012;38:600–12.
24. Ohga S, Ishiguro A, Takahashi Y, et al.; Japan Childhood Thrombophilia Study Group. Protein C deficiency as the major cause of thrombophilias in childhood. *Pediatr Int* 2013;55:267–71.
25. Ohga S, Kang D, Kinjo T, et al. Paediatric presentation and outcome of congenital protein C deficiency in Japan. *Haemophilia* 2013;19:378–84.
26. Takahashi Y, Yoshioka A. Hemostasis and its regulation system in childhood. *Jpn J Pediatr Hematol* 1994;8:389–97.
27. Athanasiadis G, Buil A, Souto JC, et al. A genome-wide association study of the protein C anticoagulant pathway. *PLoS One* 2011;6:e29168.
28. Tang W, Basu S, Kong X, et al. Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study. *Blood* 2010;116:5032–6.
29. Brummel-Ziedins KE, Orfeo T, Callas PW, Gissel M, Mann KG, Bovill EG. The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation. *PLoS One* 2012;7:e44378.
30. Matsunaga Y, Ohga S, Kinjo T, et al. Neonatal asphyxia and renal failure as the presentation of non-inherited protein C deficiency. *J Perinatol* 2013;33:239–41.
31. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. *Blood* 1986;67:362–5.
32. Wang Y, Zhao Z, Chow N, Ali T, Griffin JH, Zlokovic BV. Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. *Brain Res* 2013;1507:97–104.
33. Tsuda H, Hattori S, Tanabe S, et al. Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality. *Ann Clin Biochem* 1999;36 (Pt 4):423–32.

Survival and Neurodevelopmental Outcome of Preterm Infants Born at 22–24 Weeks of Gestational Age

Masayuki Ochiai^{a, c} Tadamune Kinjo^{a, c} Yasushi Takahata^a Mariko Iwayama^a
Takeru Abe^b Kenji Ihara^{a, c} Shouichi Ohga^{c, f} Kotaro Fukushima^{a, d}
Kiyoko Kato^{a, d} Tomoaki Taguchi^{a, e} Toshiro Hara^{a, c}

^aComprehensive Maternity and Perinatal Care Center and ^bMedical Information Center, Kyushu University Hospital, Departments of ^cPediatrics, ^dObstetrics and Gynecology, ^ePediatric Surgery and ^fPerinatal and Pediatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Key Words

Extremely premature infants · Extremely low birthweight · Mortality · Morbidity · Antenatal steroid

Abstract

Background: The limits of viability in extremely premature infants are challenging for any neonatologists in developed countries. The neurological development and growth of extremely preterm infants have come to be the emerging issue following the management in the neonatal intensive care unit. **Objective:** To assess potential associations between changes in practice and survival/neurodevelopmental outcome, and clinical outcomes of extremely preterm infants born at the limit of viability studied in a tertiary center. **Study Design:** A retrospective study enrolled 51 infants who had no congenital disorders, and were born at 22–24 weeks of gestational age (GA) in 2000–2009 in our institution. Clinical variables and interventions were studied with regard to one-year survival and developmental quotient (DQ) at 3 years of age. **Results:** The one-year survival rate of 24 preterm infants born in 2005–2009 (79%) was higher than that of the 27 infants born in 2000–2004 (52%, $p = 0.04$). Infants born after 2005 underwent less tocolysis (54 vs. 94%, $p < 0.01$) and

more frequently antenatal steroid therapy (32 vs. 6%, $p = 0.01$) than those born before 2004. The post-2005 survivors ($n = 19$) received more frequently indomethacin therapy (89 vs. 50%, $p = 0.03$) and early parenteral nutrition (95 vs. 36%, $p < 0.01$) than the pre-2004 survivors ($n = 14$). There were no differences in the proportion of infants who attained a DQ of >50 at 3 years of age between pre-2004 (9/13, 69%) and post-2005 groups (10/17, 59%). Multivariate analysis indicated that extremely premature birth at GA <24 weeks was the sole critical factor for a DQ of >50 in survivors. **Conclusions:** The perinatal care after 2005 improved the overall survival rate, but not the neurological outcome of preterm survivors at the limit of viability. Neurodevelopmental impairments were associated with extremely premature birth at GA <24 weeks.

© 2013 S. Karger AG, Basel

Introduction

Recent progress in the perinatal and neonatal care has greatly improved the prognosis of critically ill or premature newborn infants. The limits of viability in extremely premature infants are challenging for any neonatologist

KARGER

© 2013 S. Karger AG, Basel
1661–7800/14/1052–0079\$39.50/0

E-Mail karger@karger.com
www.karger.com/neo

Masayuki Ochiai, MD, PhD
Department of Pediatrics, Graduate School of Medical Sciences
Kyushu University 3-1-1 Maidashi, Higashi-ku
Fukuoka 812-8582 (Japan)
E-Mail ochimasa@pediatr.med.kyushu-u.ac.jp

in developed countries [1–4]. Between 2004 and 2007, the one-year survival rate of infants born at 22–26 weeks of gestational age (GA) in Sweden attained 70%, ranging from 9.8% at GA 22 to 85% at GA 26 weeks [5]. In 2005, the survival rates of Japanese infants during their stay in a neonatal intensive care unit (NICU) were 34.0, 54.2 and 76.6% in infants born at GA 22, 23, and 24 weeks, respectively [6]. On the other hand, the post-NICU neurological development and growth of extremely preterm infants have come to be the emerging issue.

Antenatal steroid therapy was reportedly associated with a significant decrease in the mortality of preterm infants born at GA 22–23 weeks [7]. This intervention was actively introduced in our tertiary center after 2005 for women at high risk of preterm delivery after GA 22 weeks. The alive-born premature infants are at high-risk for a constellation of life-threatening events including cerebral bleeding and sepsis. A small number of survivors at the limit of viability still have an increased risk of physiological and neurodevelopmental problems requiring long-term medical support and socioeconomic services. To assess potential associations between changes in practice and survival/neurodevelopmental outcome, we performed the present study in all infants born at GA 22–24 weeks and treated at a single tertiary center from 2000 to 2009. The favorable limits of viability and neurodevelopmental outcome are discussed with special reference to the prenatal and postnatal management.

Materials and Methods

Study Subjects

The study population included all infants delivered at GA 22–24 weeks at the Kyushu University Hospital in Japan from January 1st 2000 to December 31st 2009 (fig. 1). The maternal and neonatal records of all infants were studied retrospectively. The information collected included previous obstetric history, the present pregnancy and delivery, infant morbidity, treatment, survival, and neurodevelopmental outcome up to 3 years of age. A total of 51 alive infants, all free from congenital diseases, reached the NICU for intensive treatment.

Perinatal period was defined as comprising late pregnancy from GA 22 weeks until birth, labor and delivery, and the first week of life in accordance with the recommendations of the World Health Organization (WHO). Live birth and perinatal mortality were also defined by the WHO recommendations (<http://www.who.int/whr/2005/en/index.html>). Perinatal mortality included stillbirths and early neonatal deaths. Stillbirth was defined as fetal death before onset of labor. Intrapartum death was defined as stillbirth when the fetus was alive at the start of labor. Early neonatal death refers to a death of a live-born infant within the first 7 days of life, while death covers the remaining period up to the first year of life. GA was determined as the best obstetric estimate based




Fig. 1. Demographic characteristics of infants born at 22–24 weeks of GA delivered in 2000–2009 in our single institution. During the 10-year study period, 82 infants were delivered at GA 22–24 weeks, including 42 in 2000–2004 and 40 in 2005–2009. Of the 42 and 40 infants, 10 and 12 were stillbirths or intrapartum deaths, and the 32 and 28 were delivered as live-born infants. Of the 32 and 28 live-born infants, 5 and 4 were unable to enter the NICU because of severe asphyxia or extreme prematurity, and 27 and 24 were treated in the NICU.

on the last menstrual period, standard obstetric parameters, and ultrasonographic findings. Iatrogenic delivery represented a delivery medically or surgically induced due to maternal and/or fetal indications [8]. Antenatal steroid therapy was defined as the administration of any corticosteroid to the mother between GA 22 and 34 weeks for accelerating fetal lung maturation [9]. Surfactant administration included at least 1 dose of surfactant. Indomethacin treatment was conducted for closure of a patent ductus arteriosus (PDA) diagnosed critically or by echocardiography. Infants with body weight below the 10 percentile of the mean of the Japanese birth size standard data were classified as small for GA (SGA) [10].

Follow-up evaluations, including interval health history, neurologic evaluations, and developmental assessments (developmental quotient, DQ), were performed at 3 years of age. Developmental testing was performed using the Kyoto Scale of Psychological Development 2001 (KSPD) by trained testers. KSPD is a Japanese standard developmental test and is used to assess disabled children by most of public health centers [11]. It is an individualized face-to-face test administered by experienced psychologists to assess child’s development in the following three areas: postural-motor (fine and gross motor functions); cognitive-adaptive (non-verbal reasoning or visuospatial perceptions assessed using materials such as blocks, miniature cars, and marbles), and language-social (interpersonal relationship, socializations and verbal abilities). DQ was calculated by dividing the developmental age by chronological

Table 1. Perinatal characteristics and interventions for 60 live-born infants at GA 22–24 weeks

	2000–2004 (n = 32)	2005–2009 (n = 28)	p value
Obstetric characteristics			
CAM or p-PROM	16 (50)	17 (61)	0.28
Preeclampsia	2 (6)	6 (21)	0.09
Interventions			
Iatrogenic preterm delivery	8 (25)	8 (29)	0.49
Tocolytic treatment	30 (94)	15 (54)	<0.01
Antenatal steroid	2 (6)	9 (32)	0.01
Cesarean section	12 (38)	15 (54)	0.16
Neonatal interventions			
Intubation at birth	25 (78)	24 (86)	0.34
Surfactant administration	19 (59)	20 (71)	0.24

Figures in parentheses indicate percentages. CAM = Chorioamnionitis; p-PROM = preterm-premature rupture of membrane. Iatrogenic delivery means delivery was induced by maternal and/or fetal indications. Antenatal steroid therapy was defined as administration of any corticosteroid to the mothers between GA 22 and 34 weeks for accelerating fetal lung maturation.

age and then multiplying the quotient by 100. The mean and one standard deviation of DQ was 100.6 and 13.4, respectively. According to the protocol Japanese Society for Follow-up Study of High-Risk Infants, we defined as a normal or borderline developmental status a DQ score over 70, a mild status as a DQ from 50 to 70, and a moderate to severe status as a DQ less than 50 [12]. The study was approved by the Institutional Review Boards of Kyushu University.

Statistics

Differences between groups were tested for significance by the χ^2 test. Multivariate logistic regression analysis was conducted for survival over one year and normal to mild neurodevelopmental delay (DQ >50) as independent variables; dependent variables included perinatal characteristics, interventions and morbidities. Only dependent variables with a p value <0.25 on univariate analysis were entered into the multiple logistic models. The statistical analyses were conducted using Excel statistics (SSRI, Japan) for Windows and SPSS software (v19; SPSS, Chicago, Ill., USA). Results with p values <0.05 were considered significant.

Results

Survival of Infants Born at 22–24 Weeks of GA between 2000–2004 and 2005–2009

During the 10-year study period, a total of 82 infants were delivered at GA 22–24 weeks, including 42 in 2000–2004 and 40 in 2005–2009 (fig. 1). Ten and 12 of them

Table 2. Neonatal characteristics and interventions of survivors born at 22–24 weeks of GA over one year

	2000–2004 (n = 14)	2005–2009 (n = 19)	p value
Neonatal characteristics			
Male sex	8 (57)	9 (47)	0.84
Multiple birth	1 (7)	2 (11)	0.74
1-min Apgar score <4	8 (57)	16 (84)	0.18
5-min Apgar score <4	3 (21)	8 (42)	0.38
SGA	0 (0)	6 (32)	0.06
GA <24 weeks	6 (43)	7 (37)	0.50
Birthweight <400 g	0 (0)	2 (11)	0.32
Interventions			
High-frequency oscillation	10 (71)	19 (100)	0.05
Indomethacin	7 (50)	17 (89)	0.03
Ligation	3 (21)	6 (32)	0.80
Early parenteral nutrition	5 (36)	18 (95)	<0.01
Transfusion	13 (93)	19 (100)	0.88

Figures in parentheses indicate percentages. Infants with body weight below the 10 percentile of the mean of the Japanese birth size standard data were classified as SGA. Indomethacin treatment was performed for the closure of PDA diagnosed clinically or by echocardiography.

were stillbirths or intrapartum deaths, and 32 and 28 were delivered as live-born infants in 2000–2004 and 2005–2009, respectively. In 2000–2004, 18 (56%) infants died within 365 days of life including 15 early (0–6 days) and 3 late (7–27 days) neonatal deaths, and 14 (44%) survived over one year. In 2005–2009, 9 (32%) infants died, including 7 early and 1 late neonatal death, and 19 (68%) survived to 1 year. This difference in survival rate is statistically significant ($p = 0.04$). When perinatal characteristics and interventions were compared, the 32 live-born infants in the second period underwent less frequently maternal tocolysis (54 vs. 94%, $p < 0.01$) and more frequently antenatal steroid therapy (32 vs. 6%, $p = 0.01$) than 28 born in the first period (table 1). No other profile differed significantly between the two groups (table 2).

Survival Factors for Infants Born at 22–24 Weeks of GA

When neonatal characteristics and interventions were compared between the 14 (in 2000–2004) and 19 (in 2005–2009) survivors, the post-2005 survivors received more frequently indomethacin therapy (89 vs. 50%, $p = 0.03$) and early parenteral nutrition (95 vs. 36%, $p < 0.01$) than the pre-2004 ones (table 2).

Table 3. Clinical variables associated with a DQ >50 at 3 years of age

Variable	Infants born at 22–24 weeks of GA treated in NICU (n = 48 ¹)					
	univariate			multivariate		
	OR	95% CI	p value	OR	95% CI	p value
GA <24 weeks	0.19	0.05–0.67	0.02	0.14	0.03–0.67	0.01
Parenteral nutrition	4.82	1.38–16.76	0.02	1.01	0.09–10.78	0.99
Ligation	7.88	1.42–43.66	0.03	0.19	0.01–2.39	0.20
Transfusion	9.47	1.10–81.73	0.05	8.87	0.97–81.37	0.05
High-frequency oscillation	5.19	1.00–26.95	0.08	5.24	0.45–61.75	0.19
Indomethacin	2.43	0.74–7.98	0.24	9.75	0.67–141.9	0.10
1-min Apgar score <4	0.45	0.12–1.63	0.37			
Male sex	0.59	0.18–1.90	0.56			
Birthweight <400 g	3.29	0.28–39.16	0.70			
Iatrogenic preterm delivery	1.21	0.34–4.29	0.77			
5-min Apgar score <4	0.68	0.19–2.43	0.78			
Multiple birth	0.56	0.10–3.26	0.82			
SGA	1.17	0.23–5.94	0.85			
Cesarean section	1.11	0.35–3.54	0.86			
Tocolytic treatment	0.89	0.24–3.37	0.86			
Antenatal steroid	1.37	0.35–5.34	0.92			

OR = Odds ratio; CI = confidence interval. Logistic regression analysis was used to investigate the independent variables on a DQ >50. Obstetric characteristics and interventions, neonatal characteristics and interventions with a p value <0.25 on univariate analysis were entered into the multivariate logistic models.

¹ Three patients in whom neurodevelopmental status was not evaluated were excluded.

Neurological Morbidity of Survivors Born at 22–24 Weeks of GA at 3 Years of Age

Three patients (1 in the first and 2 in the second period) were not evaluated because of moving or being treated for malignancy. Seven (54%) of 13 evaluable survivors attained a normal or borderline developmental status (DQ >70) in 2000–2004, and 7 (41%) of 17 survivors obtained that level in 2005–2009. Four (31%) infants in the pre-2004 group and 7 (41%) in the post-2005 group had a moderate or severe developmental delay (DQ <50). The proportion of infants who attained a DQ >50 did not reach statistical significance in the first and the second study period (69 vs. 59%, $p = 0.84$).

Neurodevelopmental Factors for Attaining a DQ >50 at 3 Years of Age

The attainment of a DQ >50 in survivors at 3 years of age was negatively associated with GA <24 weeks ($p = 0.02$), and positively associated with ductus ligation ($p = 0.02$) and parenteral nutrition ($p = 0.03$) when assessed by univariate analysis. Multivariate analysis indicated a significant association only with GA <24 weeks ($p = 0.01$; table 3).

Discussion

The survival rate of infants born at GA 22–24 weeks increased significantly from 52 to 79% in a tertiary center during the decade studied. In addition, the percentage of SGA increased from 0 to 32% between the two periods. The improved survival might be due to the prenatal management including the restraint of tocolytic treatment and the more extensive use of antenatal steroid therapy, as well as to the neonatal management such as the promotion of indomethacin treatment and parenteral nutrition. However, at 3 years of age survivors born in 2005–2009 did not attain a more favorable neurodevelopment than those born in 2000–2004. The premature birth at GA <24 weeks was the most critical factor influencing neurodevelopment in survivors.

Antenatal steroid therapy has been reported to decrease the mortality of infants with GA 22–25 weeks [7, 13]. Prophylactic indomethacin may have short-term benefits for preterm infants including a reduction in the incidence of symptomatic PDA, PDA surgical ligation, and severe IVH [14]. From 2006, we routinely introduced indomethacin prophylaxis for preterm infants born at

<25 weeks of GA to reduce the risk of intraventricular hemorrhage. However, the timing of administration varied with the clinical condition of patients or individual physician preference. The nutritional problems of preterm infants have become particularly relevant to survival from NICU, as numerous studies have underlined the importance of parenteral nutrition for short- and long-term neurodevelopmental outcomes. The post-2005 survivors received more high-frequency oscillation therapy (71 vs. 100%, $p = 0.05$) than the pre-2004 ones. However, it is controversial to what extent indomethacin, parenteral nutrition and high-frequency oscillation could affect the mortality of these infants [15].

In the present study, although the survival of preterm infants at the limit of viability increased significantly over a decade, the neurodevelopment of the survivors (DQ >50), did not improve, and actually it deteriorated from 69 to 59%. However, since the total number of survivors who attained a borderline or normal development (DQ >70) was small, this trend did not reach statistical significance or was it possible to evaluate it with a multivariate analysis. We did not have enough infants in our single institute to evaluate survival and neurodevelopmental outcome at GA 22, 23 and 24 weeks. There are a few reports on the neurological outcome of survivors at GA 22 weeks [6, 16]. The cohort study of the Neonatal Research Network, Japan, revealed that the proportion of unimpaired or minimally impaired was 12.0% at GA 22 weeks and 20.0% at GA 23 weeks [17]. Infants born at GA 22–25 weeks are fragile and vulnerable to medical interventions because of the extreme immaturity of organ sys-

tems. If the survival rate increases and the neurodevelopmental impairment remains the same, the absolute number of infants with neurological problems will increase. However, the guideline for resuscitation of preterm infants at the limit of viability is still used in Japan. Based on the presented data, the probability of not only survival but also neurodevelopmental outcome of these infants is vital for counseling parents, informing care, and planning service. Recently, a prospective follow-up study of very low-birthweight infants in Japan has revealed that periventricular leukomalacia, gastrointestinal perforation, intraventricular hemorrhage, and moderate or severe bronchopulmonary dysplasia correlated with the developmental delay at 3 years of age [12]. Brain development occurs actively during the second and third trimesters of fetal life, with neurogenesis, neural migration, maturation, apoptosis, and synaptogenesis [18, 19]. Repeated courses of antenatal steroids have a promoting effect on the myelination in developing nonhuman primate brain [20]. Further studies are required to explore the significant association of antenatal steroids with long-term neurodevelopmental outcome in the light of their possible neuroprotective effects.

Acknowledgements

This study was supported in part by a grant from the Kyushu University Clinical Research Network Project, and the Japan Ministry of Education (No. 24791113). We thank Dr. Hideki Nakayama and Dr. Shunji Hikino for their involvement in the management of the preterm infants.

References

- 1 Hakansson S, Farooqi A, Holmgren PA, Serenius F, Hogberg U: Proactive management promotes outcome in extremely preterm infants: a population-based comparison of two perinatal management strategies. *Pediatrics* 2004;114:58–64.
- 2 Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD, Neo NICHD: Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993–1999. *Pediatrics* 2005;115:1645–1651.
- 3 Hoekstra RE, Ferrara TB, Couser RJ, Payne NR, Connett JE: Survival and long-term neurodevelopmental outcome of extremely premature infants born at 23–26 weeks' gestational age at a tertiary center. *Pediatrics* 2004;113:e1–e6.
- 4 Markestad T, Kaarensen PI, Ronnestad A, Reigstad H, Lossius K, Medbo S, Zanussi G, Engelund IE, Skjaerven R, Irgens LM: Early death, morbidity, and need of treatment among extremely premature infants. *Pediatrics* 2005;115:1289–1298.
- 5 Fellman V, Hellstrom-Westas L, Norman M, Westgren M, Kallen K, Lagercrantz H, Marsal K, Serenius F, Wennergren M: One-year survival of extremely preterm infants after active perinatal care in Sweden. *JAMA* 2009;301:2225–2233.
- 6 Itabashi K, Horiuchi T, Kusuda S, Kabe K, Itani Y, Nakamura T, Fujimura M, Matsuo M: Mortality rates for extremely low birth weight infants born in Japan in 2005. *Pediatrics* 2009;123:445–450.
- 7 Mori R, Kusuda S, Fujimura M: Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. *J Pediatr* 2011;159:110–114.e111.
- 8 Goldenberg RL, Culhane JF, Iams JD, Romero R: Epidemiology and causes of preterm birth. *Lancet* 2008;371:75–84.
- 9 Roberts D, Dalziel S: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 2006;CD004454.
- 10 Yoshida SH, Unno N, Kagawa H, Shinozuka N, Kozuma S, Taketani Y: Sonographic determination of fetal size from 20 weeks of gestation onward correlates with birth weight. *J Obstet Gynaecol Res* 2001;27:205–211.
- 11 Tamaru S, Kikuchi A, Takagi K, Wakamatsu M, Ono K, Horikoshi T, Kihara H, Nakamura T: Neurodevelopmental outcomes of very low birth weight and extremely low birth weight infants at 18 months of corrected age associated with prenatal risk factors. *Early Hum Dev* 2011;87:55–59.

- 12 Kono Y, Mishina J, Yonemoto N, Kusuda S, Fujimura M: Neonatal correlates of adverse outcomes in very low-birthweight infants in the NICU network. *Pediatr Int* 2011;53:930–935.
- 13 Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA, Andrews WW, Wallace D, Das A, Bell EF, Walsh MC, Laptook AR, Shankaran S, Poindexter BB, Hale EC, Newman NS, Davis AS, Schibler K, Kennedy KA, Sanchez PJ, Van Meurs KP, Goldberg RN, Watterberg KL, Faix RG, Frantz ID 3rd, Higgins RD: Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. *JAMA* 2011;306:2348–2358.
- 14 Fowlie PW, Davis PG, McGuire W: Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. *Cochrane Database Syst Rev* 2010; CD000174.
- 15 Morgan J, Young L, McGuire W: Delayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infants. *Cochrane Database Syst Rev* 2011; CD001970.
- 16 Sugiura T, Kouwaki M, Togawa Y, Sugimoto M, Togawa T, Koyama N: Neurodevelopmental outcomes at 18 months' corrected age of infants born at 22 weeks of gestation. *Neonatology* 2011;100:228–232.
- 17 Ishii N, Kono Y, Yonemoto N, Kusuda S, Fujimura M: Outcomes of infants born at 22 and 23 weeks' gestation. *Pediatrics* 2013;132:62–71.
- 18 Huttenlocher PR: Morphometric study of human cerebral cortex development. *Neuropsychologia* 1990;28:517–527.
- 19 Huttenlocher PR, Dabholkar AS: Regional differences in synaptogenesis in human cerebral cortex. *J Comp Neurol* 1997;387:167–178.
- 20 Shields A, Thomson M, Winter V, Coalson J, Rees S: Repeated courses of antenatal corticosteroids have adverse effects on aspects of brain development in naturally delivered baboon infants. *Pediatr Res* 2012;71:661–667.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Successful living domino liver transplantation in a child with protein C deficiency

Matsunami M, Ishiguro A, Fukuda A, Sasaki K, Uchida H, Shigeta T, Kanazawa H, Sakamoto S, Ohta M, Nakadate H, Horikawa R, Nakazawa A, Ishige M, Mizuta K, Kasahara M. (2015) Successful living domino liver transplantation in a child with protein C deficiency. *Pediatr Transplant*, 19: E70–E74. DOI: 10.1111/ptr.12446.

Abstract: PC is produced in the liver and inhibits blood coagulation by catalyzing active factors V and VIII. PC deficiency causes abnormal blood clotting that is difficult to regulate by anticoagulative treatments. Four reports of PC deficiency treated with LTx have been published; however, no report of DLT as a therapy for PC deficiency is available. We describe a case of a 23-month-old girl who received DLT for compound heterozygous PC deficiency. Her PC activity was below 5%. She developed intracranial lesion and frequent refractory purpura fulminans. Both her parents had heterozygous mutations of PC genes and were excluded as living donors. Furthermore, she was a low priority on the waiting list of deceased-donor transplantation. We performed living DLT using the liver from a patient with MSUD. Activated PC concentrate safely supported the perioperative period. After DLT, she maintained normal PC activities and BCAA levels. This is the first case of PC deficiency successfully treated by living DLT with MSUD. We propose that DLT using liver from patients with MSUD is a treatment option for PC deficiency.

Masatoshi Matsunami¹, Akira Ishiguro², Akinari Fukuda¹, Kengo Sasaki¹, Hajime Uchida¹, Takanobu Shigeta¹, Hiroyuki Kanazawa¹, Seisuke Sakamoto¹, Motoki Ohta³, Hisaya Nakadate², Reiko Horikawa⁴, Atsuko Nakazawa⁵, Mika Ishige⁶, Koichi Mizuta⁷ and Mureo Kasahara¹

¹Transplantation Center, National Center for Child Health and Development, Tokyo, Japan, ²Division of Hematology, National Center for Child Health and Development, Tokyo, Japan, ³Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan, ⁴Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan, ⁵Division of Clinical Pathology, National Center for Child Health and Development, Tokyo, Japan, ⁶Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan, ⁷Department of Transplant Surgery, Jichi Medical University, Tochigi, Japan

Key words: protein C deficiency – protein C concentrate – domino liver transplantation – neonatal purpura fulminans – maple syrup urine disease

Masatoshi Matsunami, MD, Transplantation Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan
Tel.: +81 3 3416 0181
Fax: +81 3 3416 2222
E-mail: matsunami-m@ncchd.go.jp

Accepted for publication 23 January 2015

Abbreviations: 3D-CT, three-dimensional computerized tomography; aPTT, activated partial thromboplastin time; BCAA, branched-chain amino acid; DDLT, deceased-donor liver transplantation; DLT, domino liver transplantation; FAP, familial amyloidotic polyneuropathy; FFP, fresh frozen plasma; HA, hepatic artery; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HV, hepatic vein; LDLT, living-donor liver transplantation; LHV, left hepatic veins; LTx, liver transplantation; M + LHV, middle and left hepatic veins; MHV, middle hepatic vein; MSUD, maple syrup urine disease; PBC, primary biliary cirrhosis; PC, protein C; PFIC, progressive familial intrahepatic cholestasis; PSC, primary sclerosing cholangitis; PT, prothrombin time; PV, portal vein; RHV, right hepatic vein.

PC is a vitamin K-dependent serine protease synthesized and secreted by liver cells as a zymogen. Activated PC downregulates the blood coagulation cascade through its proteolytic effect on factors Va and VIIIa, in conjunction with its cofactor protein S (1, 2). PC deficiency is inherited as an autosomal dominant disorder, and in most cases, derived from heterozygous mutations. Homozygous or compound heterozygous patients often suffer severe and life-threatening complications from birth. The most common presentation is purpura fulminans, a rapidly progressing hemorrhagic necrosis of the skin, which

can occur within the first few hours of birth (1, 2). Cerebral and ophthalmic damage can occur in utero, and children are often born with visual impairment. In addition, patients may suffer from venous thromboembolism (3).

Historically, the standard treatment for PC deficiency was the replacement of FFP and administration of warfarin (1, 2). In 1983, the first case of severe PC deficiency associated with neonatal purpura fulminans successfully managed by warfarin was reported (4). Since 1988, the use of PC concentrate has been widely adopted and reports of successful long-term management using PC concentrate have been published (5). Warfarin, FFP, and PC concentrate, however, are associated with thrombosis and can sometimes be difficult to administer. Hence, there is rising interest in LTx as a therapy for PC deficiency, as the liver produces PC (6–9).

To date, there are 10 reports of DLT of a recipient's metabolically defective, but structurally and functionally normal, explanted liver into a second recipient. The most common indication for DLT is FAP. With an increasing need for organs, livers explanted from patients with rare metabolic diseases, such as primary hyperoxaluria, acute intermittent porphyria, MSUD, and homozygous familial hypercholesterolemia, are being used for DLT (10–12). DLT has since become an option for increasing organ availability.

Here, we report the case of a child with severe compound heterozygous PC deficiency who was successfully treated by DLT using liver from an MSUD patient.

Case presentation

The patient was a 23-month-old girl (body weight: 9.5 kg) who was delivered by C-section because of fetal heart rate deceleration (37w 6d, 2048 g). She was the only child in the family. Multiple cerebral bleeding, subcutaneous bleeding, purpuric skin lesions on lower limbs, and vitreous hemorrhages (ultimately resulting in complete blindness) were observed shortly after birth (Fig. 1). PC activity of the patient was <5%. Genetic test performed on a blood sample confirmed that she inherited an inability to produce PC. Two heterozygous missense mutations of PC in the proband were identified c.296G>A, p.E68K and c.1109G>A, p.V339M. A low PC activity and low antigen level led to the diagnosis of compound heterozygous PC deficiency. The PC activity of the parents was also low (66% and 77%, respectively). The patient's grandmother died of cerebral bleeding, but the details were unclear. At one month of life, an ophthalmectomy was performed due to bilateral vitreous hemorrhages. Initially, the patient was managed with warfarin (0.07 mg/kg/day) and heparin (225 U/kg/day). At 14 months of age, she



Fig. 1. Skin lesions were observed on the right foot and ankle arising from peripheral thrombotic events.

suffered from symptomatic West syndrome because of past cerebral bleeding; warfarin was changed to dabigatran to control phenobarbital. However, frequent episodes of bleeding and thrombosis such as subcutaneous hematoma persisted, and FFP and activated PC concentrate were required. In addition, there was an increasing difficulty of venous line access. She was evaluated as a candidate for LTx. Both her parents had heterozygous mutations of PC genes and were excluded as living donors. Furthermore, she was a low priority on the waiting list of deceased-donor transplantation. A decision for DLT was made.

At 22 months of age, the patient was transferred to our hospital for LTx. Pre-operatively, therapy with FFP (120 mL) was instituted on alternate days until operation. There were no thrombosis and bleeding episodes before operation. In addition, she was also given dabigatran (36 mg/kg/day) and was monitored to maintain an aPTT of 60–80 s. The final dose (360 mg) was administered 48 h before induction of anesthesia and the initiation of intravenous heparin. Soon after, thrombocytopenia was recognized; heparin was discontinued, and continuous intravenous infusion of activated PC concentrate (300 U/h) commenced.

At 23 months of age, the patient underwent DLT. The first recipient was a 12-month-old-girl with MSUD, who required LDLT of the left lateral segment from a living donor because of high leucine acid, frequent metabolic acidosis, and growth impairment. As size matching between the MSUD patient and our patient was suitable, the whole liver was used as the domino graft. The whole MSUD liver was placed in the abdominal cavity and vascular reconstruction initiated. We decided the transection site of the

vessels based on 3D-CT of the first donor and recipient pre-operatively. Because the left HA of the first donor was diverged from the right gastric artery, along with sufficient anastomosis length, the gastroduodenal artery was ligated and the common HA was transected in the first recipient. As well, the RHV, the common channel of the M + LHV, was transected and the PV was transected proximal to the bifurcation. Vascular plasty of the HV was conducted on the back table. RHV, MHV, LHV, and the left superficial vein were sutured together to create one orifice. The unified graft HV was anastomosed with that of the recipient to create one orifice using all of the HV. The PV was anastomosed with the branch patch in an end-to-end fashion. The graft liver was reperfused before microsurgical reconstruction of the HA. Roux-en-Y anastomosis was employed for biliary reconstruction.

Activated PC concentrate was administered during surgery and continued until post-operative day 7. The level of PC activity increased gradually and reached 64% on post-operative day 4. In spite of the discontinuation of activated PC concentrate, PC activity levels were adequately maintained at 80–90% with PT/aPTT constantly within the normal range (Fig. 2). The recipient received a standard immunosuppressive regimen consisting of low-dose steroids and tacrolimus. On post-operative day 20, she had an episode of severe acute cellular rejection and was treated with intravenous bolus steroids therapy. On post-operative day 26, she acquired an infection of cytomegalovirus and was treated with intravenous foscarnet sodium hydrate. On post-operative day 68, she was discharged. She did not develop any BCAA imbalances or symptoms of MSUD on a normal diet with full protein




Fig. 2. Plasma PC activity levels with time after DLT.

Table 1. Amino acid levels before and after DLT

Amino acids	Normal range nmol/mL	DLT donor*		DLT recipient†	
		Before	After	Before	After
Leucine	80.9–154.3	154.6	137.9	114.4	125.3
Isoleucine	41.3–84.9	149.3	100.5	63.6	60.2
Valine	158–287.7	282.3	155.2	250.3	156.7
Alloisoleucine	ND	ND	ND	ND	ND

*Living-donor liver recipient with MSUD.

†Domino liver recipient with PC deficiency.

intake (Table 1). Six months after the DLT, PC activity was maintained at more than 80%. She remained symptom free.

All the patients and their parents gave informed consent. The study was approved by the Japanese Liver Transplantation Society and the ethical committee of each institute.

Discussion

This case highlighted two important clinical issues: PC deficiency can be successfully treated by living DLT with MSUD, and activated PC concentrate is useful and supported a safe perioperative period.

A total of 10 DLTs using livers from patients with MSUD have been reported (Table 2) (13–19). Domino livers were first considered as marginal grafts because the disease could manifest in the domino recipient (13). However, recipients of liver grafts from MSUD donors are not likely to develop protein intolerance because 60% of branched-chain ketoacid dehydrogenase activity occurs in the muscle (14). The patient and graft survival rates were 100%, and all the livers functioned normally. BCAA homeostasis was maintained with an unrestricted protein diet. MSUD livers maintained nearly normal levels of plasma

amino acids and a favorable evolution with no disease development, demonstrating structurally normal liver parenchyma with hepatic function preserved. The literature reveals four previous reports of successful LTx for PC deficiency, but there have been no reports of DLT for PC deficiency (6–9). To the best of our knowledge, this is the first case of LDLT for a pediatric recipient with MSUD, who in turn became a donor for a pediatric recipient with PC deficiency.

The use of whole liver for DLT can pose increased technical difficulty during operation (20). Livers obtained from patients with MSUD who had undergone LDLT inherently lack the retro-hepatic inferior vena cava and have multiple vessel and bile duct orifices. In this case, the MSUD patient and her living donor underwent 3D-CT before the operation to evaluate the anatomy of their HV, PV, and HA. We determined the cutting sites of the vessels based on the 3D-CT findings. The HV pedicle in the graft from the MSUD patient was short, and reconstruction was required in the second recipient. There were no surgical complications, and both recipients had good post-operative functional recovery.

Activated PC concentrate proved to be useful for perioperative management of PC deficiency. Prior to the transfer to our hospital, the patient had experienced thrombotic events and bleeding on many occasions while on FFP and dabigatran. While FFP and activated PC concentrate replacement may prevent thrombosis, they can cause fluid overload and pose a high risk of infection. Oral anticoagulant therapy, meanwhile, may risk fatal hemorrhage and often restricts normal childhood activities. Therefore, we decided to perform LTx for our patient.

Initiation of high-dose activated PC concentrate restored levels of PC in the perioperative period, allowing LTx to be performed safely in

Table 2. Outcome of DLT using MSUD

No.	LT for MSUD				DLT recipient				
	LTx	Age (yr)	Observation (m)	Outcome	Indication	Age (yr)	Observation (m)	Outcome	Study
1	DDLT	25	7	Alive	HCC and HCV	51	7	Alive	Khanna et al. (14)
2	DDLT	33	–	Alive	PSC	67	38	Alive	Gopasetty et al. (15)
3	DDLT	11	–	Alive	PFIC	24	25	Alive	Gopasetty et al. (15)
4	DDLT	18	–	Alive	Cystic fibrosis	20	18	Alive	Gopasetty et al. (15)
5	DDLT	23	–	Alive	Congenital hepatic fibrosis	22	20	Alive	Gopasetty et al. (15)
6	DDLT	22	–	Alive	PBC	52	5	Alive	Gopasetty et al. (15)
7	DDLT	5	–	Alive	Embryonal carcinoma	7	2	Alive	Gopasetty et al. (15)
8	LDLT	1	12	Alive	Biliary cirrhosis	2	12	Alive	Mohan et al. (16)
9	DDLT	24	30	Alive	Hemophilia A	52	30	Alive	Badell et al. (18)
10	LDLT	2	13	Alive	Biliary atresia	2	13	Alive	Feier et al. (19)
11	LDLT	1	6	Alive	PC deficiency	1	6	Alive	Present case

our patient. Notably, PC activity level reached 64% by post-operative day 4. Thereafter, PC activity steadily rose to adequate levels and the patient is doing well without any thrombotic events for over three months following the transplantation.

Based on the excellent results observed in this report, domino grafts from patients with MSUD could potentially be used in recipients who are low priority on the transplant waiting list and are likely to die without a transplant. Although elective DLT for PC deficiency remains controversial, reports of good outcome have established it as an acceptable therapeutic option. Furthermore, the continued success of DLT may help to mitigate existing ethical concerns. Nevertheless, prospective studies with long-term outcomes are needed to accurately determine the validity of DLT for PC deficiency.

Acknowledgment

The authors thank Professor George V. Mazariegos (Department of Pediatric Transplantation, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, USA), Professor Jean de Ville de Goyet (Department of Pediatric Surgery and Transplantation, Bambino Gesù Children's Hospital, Rome, Italy), and Professor João Seda Neto (Hepatology and Liver Transplantation, Hospital Sirio-Libanês, São Paulo, Brazil) for their advice on performing the project. Dr. Julian Tang of the Department of Education for Clinical Research, National Center for Child Health and Development, proofread and edited this manuscript.

Conflict of interest

The authors of this manuscript have no conflict of interest.

References

- PETERS C, CASELLA JF, MARLAR RA, MONTGOMERY RR, ZINKHAM WH. Homozygous protein C deficiency: Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. *Pediatrics* 1988; 81: 272–276.
- DREYFUS M, MAGNY JF, BRIDEY F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. *N Engl J Med* 1991; 325: 1565–1568.
- OHGA S, ISHIGURO A, TAKAHASHI Y, et al.; Japan Childhood Thrombophilia Study Group. Protein C deficiency as the major cause of thrombophilias in childhood. *Pediatr Int* 2013; 55: 267–271.
- BRANSON HE, KATZ J, MARBLE R, GRIFFIN JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. *Lancet* 1983; 2: 1165–1168.
- HUBBARD AR. Standardization of protein C in plasma: Establishment of an international standard. *Thromb Haemost* 1988; 59: 464–467.
- CASELLA JF, LEWIS JH, BONTEMPO FA, ZITELLI BJ, MARKEL H, STARZL TE. Successful treatment of homozygous protein C deficiency by hepatic transplantation. *Lancet* 1988; 1: 435–438.
- ANGELIS M, PEGELOW CH, KHAN FA, VERZARO R, TZAKIS AG. En bloc heterotopic auxiliary liver and bilateral renal transplant in a patient with homozygous protein C deficiency. *J Pediatr* 2001; 138: 120–122.
- FLORMAN SS, FISHBEIN TM, SCHIANO T, LETIZIA A, FENNELLY E, DeSANCHO M. Multivisceral transplantation for portal hypertension and diffuse mesenteric thrombosis caused by protein C deficiency. *Transplantation* 2002; 74: 406–407.
- LEE MJ, KIM KM, KIM JS, KIM YJ, LEE YJ, GHIM TT. Long-term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation. *Pediatr Transplant* 2009; 13: 251–254.
- WILCZEK HE, LARSSON M, YAMAMOTO S, ERICZON BG. Domino liver transplantation. *J Hepatobiliary Pancreat Surg* 2008; 15: 139–148.
- KITCHENS WH. Domino liver transplantation: Indications, techniques, and outcomes. *Transplant Rev* 2011; 25: 167–177.
- POPESCU I, DIMA SO. Domino liver transplantation: How far can we push the paradigm? *Liver Transpl* 2012; 18: 22–28.
- BARSHOP BA, KHANNA A. Domino hepatic transplantation in maple syrup urine disease. *N Engl J Med* 2005; 353: 2410–2411.
- KHANNA A, HART M, NYHAN WL, HASSANEIN T, PANYARD-DAVIS J, BARSHOP BA. Domino liver transplantation in maple syrup urine disease. *Liver Transpl* 2006; 12: 876–882.
- GOPASETTY M, SOLTYS K, BOND J, SINDHI R, NAYYAR N, MAZARIEGOS G. Domino liver transplantation from children and adults with maple syrup urine disease. *Am J Transplant* 2010; 10(Suppl 1): 68–69.
- MOHAN N, KARKRA S, KUMARAN V, et al. Twenty-two month liver recipient with maple syrup urine disease donates liver to another toddler: A report on the world's youngest domino pair. *Liver Transpl* 2010; 16(Suppl 1): S128.
- MAZARIEGOS GV, MORTON DH, SINDHI R, et al. Liver transplantation for classical maple syrup urine disease: Long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. *J Pediatr* 2012; 160: 116–121.
- BADELL IR, HANISH SI, HUGHES CB, et al. Domino liver transplantation in maple syrup urine disease: A case report and review of the literature. *Transplant Proc* 2013; 45: 806–809.
- FEIER FH, MIURA IK, FONSECA EA, et al. Successful domino liver transplantation in maple syrup urine disease using a related living donor. *Braz J Med Biol Res* 2014; 47: 522–526.
- INOMATA Y, ZELEDÓN ME, ASONUMA K, et al. Whole-liver graft without the retrohepatic inferior vena cava for sequential (domino) living donor liver transplantation. *Am J Transplant* 2007; 7: 1629–1632.

